Protective effects of synthetic kynurenines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

Brain Research Bulletin

Volumn 85, Issue 3-4, 2011, Pages 133-140

  Acuña Castroviejo, Dario ^a,b   Tapias, Victor ^a   López, Luis C ^a,b   Doerrier, Carolina ^a,b   Camacho, Encarnación ^c   Carrión, María D ^c   Mora, Francisco ^d   Espinosa, Antonio ^c   Escames, Germaine ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Inflammation; Mice; MPTP; Oxidative stress; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; INDUCIBLE NITRIC OXIDE SYNTHASE; KYNURENINE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE);

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSOL; ENZYME ACTIVITY; ENZYME INHIBITION; INFLAMMATION; MALE; MITOCHONDRION; MOUSE; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; CYTOSOL; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; KYNURENINE; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MPTP POISONING; NAD; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; OXIDATION-REDUCTION; SUBSTANTIA NIGRA;

EID: 79957802304     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.03.008     Document Type: Article

References (51)

1. Acuña-Castroviejo D., Escames G., López L.C., Hitos A.B., León J. Melatonin and nitric oxide: two required antagonists for mitochondrial homeostasis. Endocrine 2005, 27:159-168.
2. Arancio O., Kiebler M., Lee C.J., Lev-Ram V., Tsien R.Y., Kandel E.R., Hawkins R.D. Nitric oxide acts directly in the presynaptic neuron to produce long term potentiation in cultured hippocampal neurons. Cell 1996, 87:1025-1035.
3. Barrientos A. In vivo and in organello assessment of OXPHOS activities. Methods 2002, 26:307-316.
4. Blandini.F F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Func. Neurol. 2010, 25:65-71.
5. Bredt D.S. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free. Radic. Res. 1999, 31:577-596.
6. Bredt D.S., Snyder S.H. Nitric oxide mediates glutamate linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:9030-9033.
7. Brown G.C. Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim. Biophys. Acta 2001, 1504:46-57.
8. Brown G.C. Nitric oxide and neuronal death. Nitric Oxide 2010, 23:153-165.
9. Brown G.C., Boroutaite V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta 2004, 1658:44-49.
10. Camacho E., León J., Carrión M.D., Entrena A., Escames G., Khaldy H., Acuña-Castroviejo D. Inhibition of nNOS activity in rat brain by synthetic kynurenines: structure-activity dependence. J. Med. Chem. 2002, 45:263-274.
11. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
12. Escames G., Leon J., Macias M., Khaldy H., Acuña-Castroviejo D. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J. 2003, 17:932-934.
13. Esterbauer H., Cheeseman K.H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990, 186:407-421.
14. Gao Y. The multiple actions of NO. Pflugers Arch. 2010, 459:829-839.
15. Ghafourifar P., Cadenas E. Mitochondrial nitric oxide synthase. Trends Pharmacol. Sci. 2005, 26:190-195.
16. Glowinski J., Iversen L.L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem. 1966, 13:655-669.
17. Green L.C., Ruiz de Luzuriaga K., Wagner D.A., Rand W., Istfan N., Young V.R., Tannenbaum S.R. Nitrate biosynthesis in man. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:7764-7768.
18. Hallett P.J., Standaert D.J. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2004, 102:155-174.
19. Hong S.J., Dawson T.M., Dawson V.L. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signalling. Trends Pharmacol. Sci. 2004, 25:259-264.
20. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 2003, 53:S26-S36.
21. Kanai A.J., Pearce L.L., Clemens P.R., Birder L.A., VanBibber M.M., Choi S.-Y., de Groat W.C., Peterson J. Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:14126-14131.
22. Khaldy H., León J., Escames G., Bikjdaouene L., Acuña-Castroviejo D. Synergistic effects of melatonin and deprenyl protect against MPTP-induced mitochondrial damage and DA depletion. Neurobiol. Aging 2003, 24:491-500.
23. León J., Macías M., Escames G., Camacho E., Khaldy H., Martín M., Espinosa A., Gallo M.A., Acuña-Castroviejo D. Structure-related inhibition of calmodulin-dependent nNOS activity by melatonin and synthetic kynurenines. Mol. Pharmacol. 2000, 58:967-975.
24. León J., Vives F., Crespo E., Camacho E., Espinosa A., Gallo M.A., Escames G., Acuña-Castroviejo D. Modification of nitric oxide synthase activity and neuronal response in rat striatum by melatonin and kynurenine derivatives. J. Neuroendocrinol. 1998, 10:297-302.
25. León J., Vives F., Gómez I., Camacho E., Gallo M.A., Espinosa A., Escames G., Acuña-Castroviejo D. Modulation of rat striatal glutamatergic response in search for new neuroprotective agents: evaluation of melatonin and some kynurenine derivatives. Brain Res. Bull. 1998, 45:525-530.
26. Leonard J.V., Schapira A.H. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet 2000, 355:389-394.
27. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
28. Lisdero C.L., Carreras M.C., Meulemans A., Melani M., Aubier M., Boczkowski J., Poderoso J.J. The mitochondrial interplay of ubiquinol and nitric oxide in endotoxemia. Methods Enzymol. 2004, 382:67-81.
29. López L.C., Escames G., Tapias V., Utrilla P., Leon J., Acuna-Castroviejo D. Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: its relation with mitochondrial dysfunction and prevention by melatonin. Int. J. Biochem. Cell Biol. 2006, 38:267-278.
30. López A., García J.A., Escames G., Venegas C., Ortiz F., López L.C., Acuña-Castroviejo D. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J. Pineal Res. 2009, 46:188-198.
31. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
32. Marletta M.A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell 1994, 78:927-930.
33. Martín M., Macías M., Escames G., León J., Acuña-Castroviejo D. Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J. 2000, 14:1677-1679.
34. Moratalla R., Quinn B., DeLanney L.E., Irwin I., Langston J.W., Graybiel A.M. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:3859-3863.
35. Nakamura T., Lipton S.A. S-Nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Antioxid. Redox Signal. 2010, 3570. doi:10.1089/ars.2010.
36. Navarro A., Bández M.J., Gómez C., Repetto M.G., Boveris A. Effects of rotenone and pyridaben on complex I electron transfer and on mitochondrial nitric oxide synthase functional activity. J. Bioenerg. Biomembr. 2010, 10.1007/s10863-010-9309-4.
37. Navarro A., Boveris A. Brain mitochondrial dysfunction and oxidative damage in Parkinson's disease. J. Bioenerg. Biomembr. 2009, 41:517-521.
38. Niranjan R., Nath C., Shukla R. The mechanism of action of MPTP-induced neuroinflammation and its modulation by melatonin in rat astrocytoma cells, C6. Free Radic. Res. 2010, 44:1304-1316.
39. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G., Marin C., Kordower J.H., Rodriguez M., Hirsch E.C., Farrer M., Schapira A.H., Halliday G. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16:653-661.
40. Oh J.D., Chase T.N. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 2002, 23:133-139.
41. Parihar M.S., Parihar A., Villamena F.A., Vaccaro P.S., Ghafourifar P. Inactivation of mitochondrial respiratory chain complex I leads mitochondrial nitric oxide synthase to become pro-oxidative. Biochem. Biophys. Res. Commun. 2008, 367:761-767.
42. Przedborski S., Tieu K., Perier C., Vila M. MPTP as a mitochondrial neurotoxin model of Parkinson's disease. J. Bioenerg. Biomembr. 2004, 36:375-379.
43. Rao V.R., Finkbeiner S. NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci. 2007, 30:284-291.
44. Rego A.C., Oliveira C.R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem. Res. 2003, 28:1563-1574.
45. Riobo N.A., Clementi E., Melani M., Boveris A., Cadenas E., Moncada S., Poderoso J.J. Nitric oxide inhibits mitochondrial NADH: ubiquinone reductase activity through peroxynitrite formation. Biochem. J. 2001, 359:139-145.
46. Schapira A.H. Complex I: inhibitors, inhibition and neurodegeneration. Exp. Neurol. 2010, 224:331-335.
47. Speciale S.G. MPTP: insights into parkinsonian neurodegeneration. Neurotoxicol. Teratol. 2002, 24:607-620.
48. Stout A.K., Raphael H.M., Kanterewicz B.I., Klann E., Reynolds I.J. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat. Neurosci. 1998, 1:366-373.
49. 1-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J. Neurosci. Res. 2009, 87:3002-3010.
50. Traaseth N., Elfering S., Solien J., Haynes V., Giulivi C. Role of calcium signaling in the activation of mitochondrial nitric oxide synthase and citric acid cycle. Biochim. Biophys. Acta 2004, 1658:64-71.
51. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552:335-344.